Blog

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Nov 1 • 7 min read

–interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) – – For reference, pooled data from 232 industry studies of current standard of…

The Peyote Predicament: A Controversial Debate in the Psychedelic Industry

Oct 27 • 7 min read

As the psychedelic movement transforms and develops into a new entity, there is bound to be internal conflict and opposition. The fight to include indigenous voices in the emerging industry and ensure that native communities are honored has garnered a great deal of attention this year. This debate has been particularly heated when it comes…

PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics

Oct 27 • 5 min read

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company“), is pleased to announce that it has entered into a definitive agreement (the “Acquisition Agreement“) dated October 27, 2023 pursuant to which PharmaDrug will acquire all of the issued and outstanding shares of privately-held Securedose Synthetics Inc. (“SecureDose“), to be effected by way of…

Beckley Waves Acquires Nue Life

Oct 26 • 3 min read

Strengthens its Network of Psychedelic Care Infrastructure Beckley Waves, the first venture studio focused on building and investing companies in the thriving psychedelic ecosystem to advance mental health and well-being, announced today the strategic acquisition of Nue Life, a leading ketamine-assisted therapy provider. Beckley Waves will continue Nue Life’s work to provide safe and scalable access…

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Oct 26 • 3 min read

– European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated DMT programs – – New European patent further strengthens intellectual property portfolio, which now includes 33 granted patents and over 170 pending applications – Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538